

## Sponsored Symposium

## NEW INSIGHTS INTO THE MOLECULAR MECHANISM OF ACTION OF PPAR-alpha AGONISTS

Chairpersons: **Brewer H.B., Jr.** (Bethesda, USA)  
**Crepaldi G.** (Padua, Italy)

hour:		abstract bk. page ref.:
14.00 – 14.05	OPENING REMARKS <b>Crepaldi G.</b> (Padua, Italy)	–
14.05 – 14.25	PLEIOTROPIC ANTI-INFLAMMATORY EFFECTS OF PPAR-alpha AGONISTS RELEVANT TO ATHEROSCLEROSIS <b>Libby P.</b> (Boston, USA)	2
14.25 – 14.45	APO AV: A KEY PLAYER IN TRIGLYCERIDES METABOLISM <b>Fruchart J.-C.</b> (Lille, France)	2
14.45 – 15.05	HEPATIC REGULATION OF INFLAMMATORY MARKERS OF ATHEROSCLEROSIS <b>Staels B.</b> (Lille, France)	2
15.05 – 15.25	CLINICAL BENEFITS OF FIBRATES ON NON-LIPID PARAMETERS <b>Zambon A.</b> (Padua, Italy)	2
15.25 – 15.40	GENERAL DISCUSSION	–
15.40 – 15.45	CLOSING REMARKS <b>Brewer H.B., Jr.</b> (Bethesda, USA)	–
15.45	<i>End of the Session</i>	

Supported by an unrestricted educational grant provided by Fournier Pharma

*A service of simultaneous translation (English-Italian-English) will be provided for this Symposium.*

15.45 - 16.45 *POSTER DISCUSSION AT THE POSTER SITE WITH THE AUTHORS*  
*Group A (Poster Sessions 1 – 6; see Final Programme Pages 23 - 31)*

## Sponsored Symposium

## DUAL PPAR AGONISTS: A NOVEL APPROACH TO TREATING HYPERGLYCEMIA AND DYSLIPIDEMIA

Chairpersons: **Fruchart J.-C.** (Lille, France)  
**Paoletti R.** (Milan, Italy)

hour:		abstract bk. page ref.:
14.00 – 14.05	OPENING REMARKS <b>Paoletti R.</b> (Milan, Italy)	–
14.05 – 14.20	CURRENT CHALLENGES FOR TREATING HYPERGLYCAEMIA AND DYSLIPIDAEMIA IN TYPE 2 DIABETES <b>Heine R.J.</b> , Salden N., Nijpels G. (Amsterdam, The Netherlands)	9
14.20 – 14.35	A BASIC UNDERSTANDING OF DUAL PPAR AGONISTS <b>Wright S.D.</b> (Rahway, USA)	9
14.35 – 14.50	POTENTIAL CLINICAL UTILITY OF NOVEL DUAL PPAR AGONISTS <b>Mercuri M.</b> (Rahway, USA)	9
14.50 – 14.55	CLOSING REMARKS <b>Fruchart J.-C.</b> (Lille, France)	–
14.55	<i>End of the Session</i>	
14.55 – 16.00	<i>Break</i>	

Supported by an unrestricted educational grant provided by Merck & Co., Inc.

*A service of simultaneous translation (English-Italian-English) will be provided for this Symposium.*

## Sponsored Symposium

## FULFILLING THE POTENTIAL OF PPAR LIGANDS IN TYPE 2 DIABETES

Chairpersons: **Law R.E.** (Los Angeles, USA)  
**Staels B.** (Lille, France)

hour:		abstract bk. page ref.:
14.00 – 14.05	OPENING REMARKS <b>Staels B.</b> (Lille, France)	–
14.05 – 14.30	INSULIN RESISTANCE AND CARDIOVASCULAR RISK <b>Roden M.</b> (Vienna, Austria)	<b>16</b>
14.30 – 14.55	ROLE OF PPARs IN PRESERVING THE BETA-CELL <b>Burant C.F.</b> (Ann Arbor, USA)	<b>16</b>
14.55 – 15.00	CLOSING REMARKS <b>Law R.E.</b> (Los Angeles, USA)	–
15.00	<i>End of the Session</i>	
15.00 – 15.45	<i>Break</i>	

Supported by an unrestricted educational grant provided by Takeda Pharmaceuticals North America, Inc. and Takeda Europe Research and Development Center Ltd.

*A service of simultaneous translation (English-Italian-English) will be provided for this Symposium.*

15.45 – 16.45 *POSTER DISCUSSION AT THE POSTER SITE WITH THE AUTHORS  
Group B (Poster Sessions 7 – 12; see Final Programme Pages 32 - 42)*